| scholarly article | Q13442814 |
| P50 | author | Jose M Rubio | Q87796423 |
| P2093 | author name string | Christoph U Correll | |
| John M Kane | |||
| P2860 | cites work | Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis | Q40099438 |
| Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions | Q40136199 | ||
| Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study | Q40228281 | ||
| Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings. | Q40376876 | ||
| Longitudinal study of brain morphology in first episode schizophrenia | Q40718665 | ||
| Does long term use of psychiatric drugs cause more harm than good? | Q40928053 | ||
| Premature Mortality Among Adults With Schizophrenia in the United States. | Q41176091 | ||
| Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder | Q41280845 | ||
| Excess mortality in severe mental illness: 10-year population-based cohort study in rural Ethiopia | Q41470845 | ||
| Personalized Prediction of Psychosis: External Validation of the NAPLS-2 Psychosis Risk Calculator With the EDIPPP Project. | Q41630931 | ||
| Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis | Q41658698 | ||
| D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis | Q42056580 | ||
| Effect of lifestyle coaching versus care coordination versus treatment as usual in people with severe mental illness and overweight: Two-years follow-up of the randomized CHANGE trial | Q42371406 | ||
| Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention | Q42692847 | ||
| Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia | Q43149273 | ||
| Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. | Q43694433 | ||
| Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia | Q43787435 | ||
| The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements | Q22242826 | ||
| Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor | Q22242831 | ||
| A Systematic Review of Mortality in Schizophrenia | Q22253025 | ||
| Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy | Q23009758 | ||
| Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium | Q23747506 | ||
| A systematic review and meta-analysis of recovery in schizophrenia | Q26859162 | ||
| Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives | Q26863435 | ||
| Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? | Q28109603 | ||
| A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication | Q28144347 | ||
| Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies | Q28247669 | ||
| Cerebral ventricular size and cognitive impairment in chronic schizophrenia | Q28263146 | ||
| Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis | Q28266069 | ||
| Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis | Q28293647 | ||
| Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. | Q30379171 | ||
| Alterations in the hippocampus and thalamus in individuals at high risk for psychosis. | Q30381309 | ||
| The neuropathology of schizophrenia. A critical review of the data and their interpretation | Q30573678 | ||
| Laterality interacts with sex across the schizophrenia/bipolarity continuum: an interpretation of meta-analyses of structural MRI. | Q30665408 | ||
| Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? | Q30695945 | ||
| Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program | Q30797835 | ||
| The neuropathology of schizophrenia: A selective review of past studies and emerging themes in brain structure and cytoarchitecture | Q30977022 | ||
| Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies | Q31023592 | ||
| Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials | Q33425007 | ||
| The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements | Q33566124 | ||
| Differences in mortality and suicidal behaviour between treated and never-treated people with schizophrenia in rural China | Q33572071 | ||
| Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls | Q33670588 | ||
| Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis | Q39015229 | ||
| Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis | Q39233778 | ||
| Tardive dyskinesia: review and update | Q40082882 | ||
| Declining Clinical Course of Psychotic Disorders Over the Two Decades Following First Hospitalization: Evidence From the Suffolk County Mental Health Project | Q40095934 | ||
| Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes | Q44155989 | ||
| Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis | Q44435116 | ||
| Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study | Q44695213 | ||
| Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method | Q45295760 | ||
| Longitudinal changes in magnetic resonance imaging brain volumes in abstinent and relapsed alcoholics. | Q45988791 | ||
| Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study | Q46827879 | ||
| Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis | Q47101583 | ||
| Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders | Q47274758 | ||
| The Relationship Between Clinical and Personal Recovery in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-analysis. | Q47567149 | ||
| Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice | Q47618934 | ||
| Stability and development of psychotic symptoms and the use of antipsychotic medication - long-term follow-up | Q47755626 | ||
| The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. | Q47945243 | ||
| Brain Structural Abnormalities in a Group of Never-Medicated Patients With Long-Term Schizophrenia. | Q48123812 | ||
| Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry | Q48229217 | ||
| Reversibility of brain tissue loss in anorexia nervosa assessed with a computerized Talairach 3-D proportional grid | Q49096363 | ||
| A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. | Q50652601 | ||
| Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. | Q50660859 | ||
| Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. | Q51903646 | ||
| Neuroleptic withdrawal with remitted schizophrenics: a naturalistic follow-up study. | Q51903792 | ||
| Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis. | Q51947455 | ||
| Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. | Q51953902 | ||
| Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. | Q52652401 | ||
| Duration and Relevance of Untreated Psychiatric Disorders, 1: Psychotic Disorders. | Q53366604 | ||
| Accuracy of Clinician Assessments of Medication Status in the Emergency Setting: A Comparison of Clinician Assessment of Antipsychotic Usage and Plasma Level Determination. | Q53393722 | ||
| A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. | Q55054009 | ||
| Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. | Q55054896 | ||
| Schizophrenia | Q56959104 | ||
| Apparent Cerebral Atrophy in Patients on Treatment with Steroids | Q57311455 | ||
| Longitudinal Volume Reductions in People at High Genetic Risk of Schizophrenia as They Develop Psychosis | Q57316778 | ||
| Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia | Q57402860 | ||
| Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia | Q57616603 | ||
| Brain Volume Changes After Withdrawal of Atypical Antipsychotics in Patients With First-Episode Schizophrenia | Q60610017 | ||
| Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization | Q63951925 | ||
| Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia | Q69899091 | ||
| A prospective study of tardive dyskinesia development: preliminary results | Q72537133 | ||
| Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical disectors | Q72734923 | ||
| Tardive dyskinesia circa 2006 | Q80025605 | ||
| A critique of the "ultra-high risk" and "transition" paradigm | Q33670654 | ||
| Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study | Q33714619 | ||
| Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. | Q33814201 | ||
| Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study | Q33923683 | ||
| Practice guideline for the treatment of patients with schizophrenia, second edition. | Q33976372 | ||
| Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse | Q33996824 | ||
| 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). | Q34018491 | ||
| Assessment of mortality and marital status of schizophrenic patients over a period of 13 years | Q34034344 | ||
| Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics | Q34054683 | ||
| Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia | Q34317536 | ||
| Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. | Q34337272 | ||
| Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. | Q34351095 | ||
| Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry | Q34357174 | ||
| Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain | Q34363450 | ||
| Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. | Q34415975 | ||
| The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies | Q34468314 | ||
| Antipsychotic Maintenance Treatment: Time to Rethink? | Q34488215 | ||
| "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time | Q34577698 | ||
| Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. | Q34623350 | ||
| Depot antipsychotic drugs. Place in therapy | Q34719546 | ||
| Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia | Q34861424 | ||
| Oxidative mechanisms and tardive dyskinesia | Q35017644 | ||
| Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies | Q35042829 | ||
| Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis | Q35065378 | ||
| Clinical predictors of therapeutic response to antipsychotics in schizophrenia | Q35109168 | ||
| Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. | Q35165445 | ||
| Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database | Q35249595 | ||
| Antipsychotic treatment and mortality in schizophrenia | Q35369872 | ||
| Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder | Q35754726 | ||
| Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. | Q35777332 | ||
| Quantifying clinical relevance in the treatment of schizophrenia | Q35819467 | ||
| Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment | Q35960362 | ||
| Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis | Q36118736 | ||
| Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries | Q36200262 | ||
| Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China | Q36333267 | ||
| Cognitive behavior therapy for schizophrenia | Q36412204 | ||
| Reversible brain shrinkage in abstinent alcoholics, measured by MRI. | Q36439736 | ||
| The current unsatisfactory state of relapse prevention in schizophrenic psychoses--suggestions for improvement | Q36537076 | ||
| Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. | Q36654304 | ||
| A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. | Q36692829 | ||
| Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study | Q36784855 | ||
| Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment. | Q36838322 | ||
| Physical illness and schizophrenia: a review of the literature | Q36962153 | ||
| Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis | Q37015327 | ||
| The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesi | Q37015355 | ||
| Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects | Q37131066 | ||
| Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study | Q37131080 | ||
| Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies | Q37236148 | ||
| A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls | Q37236162 | ||
| Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials | Q37451403 | ||
| Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia | Q37584279 | ||
| Metabolic and cardiovascular adverse effects associated with antipsychotic drugs | Q37947095 | ||
| Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms | Q37966430 | ||
| Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. | Q38015565 | ||
| Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review | Q38200893 | ||
| Clinically meaningful biomarkers for psychosis: a systematic and quantitative review | Q38216050 | ||
| A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. | Q38382821 | ||
| Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study | Q38397353 | ||
| Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. | Q38680307 | ||
| A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia | Q38708602 | ||
| Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia | Q38737194 | ||
| Reduced Thickness of the Anterior Cingulate Cortex in Individuals With an At-Risk Mental State Who Later Develop Psychosis | Q38740436 | ||
| The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia | Q38803633 | ||
| Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders | Q38815462 | ||
| Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. | Q38855787 | ||
| Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis | Q38918200 | ||
| Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics | Q38921307 | ||
| Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis | Q38942045 | ||
| Five-fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis | Q38981879 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 149-160 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | World Psychiatry | Q8036083 |
| P1476 | title | What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? | |
| P478 | volume | 17 |
| Q86591610 | 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20) |
| Q90620603 | A critical analysis of recent data on the long-term outcome of antipsychotic treatment |
| Q99545938 | A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders |
| Q92441287 | A systematic review of genome-wide association studies of antipsychotic response |
| Q90116242 | Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia |
| Q97521512 | Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder |
| Q64910974 | Basic symptoms in offspring of parents with mood and psychotic disorders. |
| Q64910620 | Cardiac structure and function in patients with schizophrenia taking antipsychotic drugs: an MRI study. |
| Q90259306 | Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia |
| Q102388982 | Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation |
| Q90198639 | Exercise as Medicine for Mental and Substance Use Disorders: A Meta-review of the Benefits for Neuropsychiatric and Cognitive Outcomes |
| Q100416111 | Identifying and validating subtypes within major psychiatric disorders based on frontal-posterior functional imbalance via deep learning |
| Q89572022 | Influence of More Than 5 Years of Continuous Exposure to Antipsychotics on Cerebral Functional Connectivity of Chronic Schizophrenia |
| Q93092613 | Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities |
| Q60949949 | Less Medication Use in Inpatients With Severe Mental Illness Receiving a Multidisciplinary Lifestyle Enhancing Treatment. The MULTI Study III |
| Q91790829 | Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons |
| Q98891298 | Mesenchymal stem cells derived extracellular vesicles improve behavioral and biochemical deficits in a phencyclidine model of schizophrenia |
| Q90264515 | Predictors for Antipsychotic Dosage Change in the First Year of Treatment in Schizophrenia Spectrum and Bipolar Disorders |
| Q91326524 | Psychiatric management of anti-NMDAR encephalitis: a cohort analysis |
| Q92695687 | Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study |
| Q98627662 | Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis |
| Q57715244 | The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study |
| Q93192452 | The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory |
| Q96773916 | The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia |
| Q98289116 | The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review |
| Q89842585 | The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index |
Search more.